Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 1
1981 1
1982 1
1983 1
1984 3
1986 1
1988 1
1989 3
1990 7
1991 6
1992 4
1993 7
1994 9
1995 9
1996 5
1997 14
1998 6
1999 7
2000 11
2001 7
2002 11
2003 14
2004 21
2005 19
2006 9
2007 20
2008 11
2009 6
2010 20
2011 10
2012 10
2013 14
2014 12
2015 14
2016 13
2017 11
2018 6
2019 12
2020 18
2021 16
2022 23
2023 23
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.
Fu K, Xie F, Wang F, Fu L. Fu K, et al. J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4. J Hematol Oncol. 2022. PMID: 36482474 Free PMC article. Review.
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. ...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell
Neuroendocrine neoplasms of the esophagus and stomach.
Mastracci L, Rindi G, Grillo F, Solcia E, Campora M, Fassan M, Parente P, Vanoli A, La Rosa S. Mastracci L, et al. Pathologica. 2021 Feb;113(1):5-11. doi: 10.32074/1591-951X-229. Pathologica. 2021. PMID: 33686305 Free PMC article. Review.
Among E-NENs, exceptionally rare well differentiated neuroendocrine tumors (E-NET) and more frequent esophageal poorly differentiated neuroendocrine carcinomas (E-NEC) and mixed neuroendocrine-non neuroendocrine neoplasms (MiNEN) can be recogniz …
Among E-NENs, exceptionally rare well differentiated neuroendocrine tumors (E-NET) and more frequent esophageal poorly differe …
The role of bile acids in carcinogenesis.
Režen T, Rozman D, Kovács T, Kovács P, Sipos A, Bai P, Mikó E. Režen T, et al. Cell Mol Life Sci. 2022 Apr 16;79(5):243. doi: 10.1007/s00018-022-04278-2. Cell Mol Life Sci. 2022. PMID: 35429253 Free PMC article. Review.
The majority of the intestinal bile acids undergo reuptake and return to the liver. A small fraction of secondary and primary bile acids remains in the circulation and exert receptor-mediated and pure chemical effects (e.g. acidic bile in oesophageal cancer) on canc …
The majority of the intestinal bile acids undergo reuptake and return to the liver. A small fraction of secondary and primary bile ac …
Mediastinal Staging in Non-Small-Cell Lung Cancer: Saying Goodbye to Mediastinoscopy.
Dunne EG, Fick CN, Jones DR. Dunne EG, et al. J Clin Oncol. 2023 Aug 1;41(22):3785-3790. doi: 10.1200/JCO.23.00867. Epub 2023 Jun 2. J Clin Oncol. 2023. PMID: 37267507 Review.
The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice.Accurate staging of the mediastinal lymph nodes in resectable non-sm
The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal o …
Futibatinib: First Approval.
Syed YY. Syed YY. Drugs. 2022 Dec;82(18):1737-1743. doi: 10.1007/s40265-022-01806-z. Drugs. 2022. PMID: 36441501 Review.
Futibatinib (Lytgobi()) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1-4 that is being developed by Taiho Oncology and Taiho Pharmaceutical for the treatment of cancers, including cholangiocarcinoma, breast cancer, gastric canc …
Futibatinib (Lytgobi()) is an oral, covalently binding, irreversible inhibitor of fibroblast growth factor receptor (FGFR)1-4 that is being …
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Aupérin A, et al. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29. J Clin Oncol. 2010. PMID: 20351327 Review.
PURPOSE: The previous individual patient data meta-analyses of chemotherapy in locally advanced non-small-cell lung cancer (NSCLC) showed that adding sequential or concomitant chemotherapy to radiotherapy improved survival. ...CONCLUSION: Concomitant radiochemothera …
PURPOSE: The previous individual patient data meta-analyses of chemotherapy in locally advanced non-small-cell lung cancer (NS …
Role of miR-424 in the carcinogenesis.
Ghafouri-Fard S, Askari A, Hussen BM, Taheri M, Akbari Dilmaghani N. Ghafouri-Fard S, et al. Clin Transl Oncol. 2024 Jan;26(1):16-38. doi: 10.1007/s12094-023-03209-2. Epub 2023 May 13. Clin Transl Oncol. 2024. PMID: 37178445 Free PMC article. Review.
Experiments in the ovarian cancer, cervical cancer, hepatocellular carcinoma, neuroblastoma, breast cancer, osteosarcoma, intrahepatic cholangiocarcinoma, prostate cancer, endometrial cancer, non-small cell lung cancer, hemangioma and gastric cancer have repo …
Experiments in the ovarian cancer, cervical cancer, hepatocellular carcinoma, neuroblastoma, breast cancer, osteosarcoma, intrahepati …
Sugemalimab: First Approval.
Dhillon S, Duggan S. Dhillon S, et al. Drugs. 2022 Apr;82(5):593-599. doi: 10.1007/s40265-022-01693-4. Drugs. 2022. PMID: 35298827 Review.
In December 2021, sugemalimab was approved in China for the first-line treatment of epidermal growth factor receptor (EGFR) gene mutation and anaplastic lymphoma kinase (ALK) negative metastatic non-small cell lung cancer (NSCLC) administered in combination with pem …
In December 2021, sugemalimab was approved in China for the first-line treatment of epidermal growth factor receptor (EGFR) gene mutation an …
Primary small cell carcinoma of the esophagus: patient data metaanalysis and review of the literature.
Al Mansoor S, Ziske C, Schmidt-Wolf IG. Al Mansoor S, et al. Ger Med Sci. 2013 Aug 23;11:Doc12. doi: 10.3205/000180. eCollection 2013. Ger Med Sci. 2013. PMID: 23983673 Free PMC article. Review.
We analysed the typical features of primary small cell carcinoma of the esophagus (SCCE) with emphasis on occurrence, behaviour, outcome and treatment options. ...We finally analysed 313 patient cases from the literature with oesophageal SCC. A data ex …
We analysed the typical features of primary small cell carcinoma of the esophagus (SCCE) with emphasis on occurrence, b …
Immunotherapy for non-small cell lung cancer.
Kagamu H. Kagamu H. Respir Investig. 2024 Mar;62(2):307-312. doi: 10.1016/j.resinv.2024.01.011. Epub 2024 Feb 3. Respir Investig. 2024. PMID: 38310751 Review.
Immune checkpoint inhibitors (ICI) bind to programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) and Cytotoxic T-lymphocyte antigen-4 (CTLA-4), which suppress T-cell function and inhibit their inhibitory function, resulting in T-cell activation. ICI have been …
Immune checkpoint inhibitors (ICI) bind to programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) and Cytotoxic T-lymphocyte antigen-4 …
403 results